Discussion  by unknown
prognostic potential of acute and delayed stent graft place-
ment in patients with thoracic aortic dissection.
In conclusion, endovascular treatment for thoracic aortic
dissection with the Talent stent graft carried out at high-vol-
ume referral centers is associated with low early morbidity
and mortality rates also for patients at high risk and treated
on an emergency basis. Follow-up data indicate a satisfactory
midterm durability of the procedure with an estimated
95.0% freedom from related death and an estimated
75.5% freedom from secondary interventions at 2 years. Al-
though preliminary data suggest that stent graft repair may
ultimately become the treatment of choice for most patients
with distal dissections, the available evidence to date does
not justify indiscriminate use of this technology in patients
currently managed with medical therapy alone. Long-term
surveillance will be crucial to discover complications unique
to thoracic endovascular interventions and to determine
which patients are appropriate candidates for stent graft
therapy. Most important, comparative clinical trials are
clearly needed to clarify the role of stent graft repair in the
setting of both acute and chronic distal dissection.
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Discussion
Dr R. Scott Mitchell (Stanford, Calif). I congratulate you on
a truly fine presentation. It is a difficult subject. You and your co-
authors report on a subject of great interest, that is, the long-term
utility of endografts in both acute and chronic dissections. Al-
though stent grafts may be truly lifesaving for patients with acute
dissections who have malperfusion or impending rupture, many
of us harbor significant reservations regarding their utility in un-
complicated type B dissections or in any chronic dissection. In
this respect, 20% of your patients were treated urgently for acute
complications, whereas the remainder were treated in a stable con-
dition. In-hospital mortality occurred in 5% of patients, 2 of whom
died intraoperatively from ruptures of their dissection, which al-
ways is a very challenging patient cohort. Not surprisingly, older
age, emergency status, and increasing ASA scores were indepen-
dent predictors. Four patients had retrograde type A dissections
in the acute phase, and 2 other patients had late type A dissections.
This brings me to my first question. Do you have any information
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about these patients? Was it difficult to achieve a proximal seal?
Did they get ballooning at the proximal anastomosis or proximal
extensions? Can you elucidate on that?
Dr Ehrlich. Four of 7 patients had retrograde type A dissection
within 30 days, and there is no doubt that this complication was as-
sociated with the stent-graft implantation. The only predictor that
turned out to be statistically significant was the use of more stents,
speculating that most of those patients did not have a sealing of the
primary tear in the first place. An additional stent was positioned in
the proximal arch with balloon dilatation, and as a consequence of
the procedure an intimal tear with retrograde dissection developed.
With regard to the 3 patients who had retrograde type A dissec-
tion after discharge, we can only speculate that it might have been
some complication of the stent-graft treatment. All of those patients
were operated on, and a new type A dissection developed in some
of them, but we do not have any information on those 3 patients.
DrMitchell. Overall, as you noted, early results were good, but
the late results are of more interest. Here, unfortunately, informa-
tion is more limited. Although survival at 36 months was 81%,
this is a limited measure of success inasmuch as 80% of these pa-
tients were really treated in the uncomplicated and asymptomatic
state. More important would be what happened to the aortas in these
chronic dissections? You tell us that despite a 20% incidence of pri-
mary type I endoleaks, an increase in aortic size occurred in only
20% of patients, and 55% and 25%, respectively, showed no
change in size or a decrease. However, and herein lies my problem
with this paper, only 60% of patients had any imaging past 12
months. Although survival and freedom from reintervention rates
are good, we really do not know what happened to the aortas in
these patients in the late stage. Thus, I have three other questions.
I noted that 15 patients with the Marfan syndrome were treated
and that Marfan actually in the univariate analysis was a predictor
of in-hospital death. Do you still recommend stent-graft treatment
for primary dissections in patients with Marfan syndrome?
Dr Ehrlich. Thank you, Dr. Mitchell, for this excellent com-
ment. Fifteen patients with Marfan syndrome were included in
the study. Two of them had acute complicated type B dissection,
in which I see the only indication for stent-graft placement probably
as a bridging procedure to late elective surgery. The other 13 pa-
tients had chronic type B dissection. In my personal opinion, I
would not recommend stent grafting for these patients, as they
are usually relatively young and I think they would have a relatively
low morbidity or mortality if they where to be operated on conven-
tionally.
Dr Mitchell. We concur with that entirely.
With regard to spinal cord injury, did this appear in the acute
phase or were these delayed paraplegias? Do we have any infor-
mation as to the distal extent of your stent grafts? We are partic-
ularly paranoid about allowing our stent grafts below the T6 or T7
level.
Dr Ehrlich. Spinal cord injury developed in 4 patients, and the
injury occurred right after stent-graft placement. There were no in-
stances of delayed onset of paraplegia. However, in 2 patients, the
paraplegia resolved, resulting in a permanent paraplegia rate of 2%.
It must be stressed, however, that in none of these patients was the
left subclavian artery overstented and in none of these patients were
multiple stents used.
DrMitchell. In cases of chronic dissection, do you have any in-
formation on the behavior of the false lumen or thrombosis thereof
during late follow-up?
I applaud your attempt to provide critical information on this dif-
ficult patient cohort.
Dr Ehrlich. The false lumen was thrombosed in 59% of all pa-
tients. It was partially thrombosed in 20%, and no thrombosis oc-
curred in 20%. However, we saw a trend that in acute type B
dissection the rate of false lumen thrombosis was higher.
Dr Thomas M. Beaver (Gainesville, Fla). I am curious about
the 29% incidence of endoleaks, or primary type I endoleaks, and
the reasons for reintervention. Traditionally, type B dissections
are treated medically and if the aorta is not aneurysmal, we would
not be intervening. What were the reasons for intervention on the
type I endoleaks?
Dr Ehrlich. The major finding in this study is that acute compli-
cated type B dissection can be nicely treated with a stent device;
however, in chronic type B dissection the results were very bleak
and actually comparable to medical treatment. I think our data
are confirmed by the INSTEAD* trial, or, let’s say differently,
the INSTEAD trial confirms our observation that probably patients
with chronic type B dissections are better off with medical
treatment.
Dr D. Craig Miller (Stanford, Calif). I also have reviewed this
paper. The results in the patients with complicated acute type B
dissections, people dying right under your nose, are superb. You
do have some 1- to 2-year data that show this is really where this
technology is going to save lives. Conversely, you have not per-
suaded me that stent grafting offers any favorable effects or protec-
tion for patients with chronic uncomplicated dissections. Just
because stent grafting can be done with low morbidity and mortal-
ity risk does not mean it should be done.
Dr Ehrlich. I fully agree with you.
Dr Miller. Your coauthors may not, though. This is difficult for
Marek as he is representing a very diverse group of interventional
radiologists and cardiologists and cardiac surgeons from many dif-
ferent centers.
* INSTEAD= INvestigation of STEnt grafts in patients with type B Aortic Dissection.
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